Logo image of XPEV

XPENG INC - ADR (XPEV) Stock Fundamental Analysis

NYSE:XPEV - New York Stock Exchange, Inc. - US98422D1054 - ADR - Currency: USD

19.98  -0.69 (-3.34%)

After market: 20.03 +0.05 (+0.25%)

Fundamental Rating

3

XPEV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 38 industry peers in the Automobiles industry. XPEV may be in some trouble as it scores bad on both profitability and health. XPEV is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

XPEV had negative earnings in the past year.
In the past year XPEV has reported a negative cash flow from operations.
XPEV had negative earnings in each of the past 5 years.
XPEV had negative operating cash flow in 4 of the past 5 years.
XPEV Yearly Net Income VS EBIT VS OCF VS FCFXPEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2B -4B -6B -8B -10B

1.2 Ratios

XPEV has a better Return On Assets (-7.00%) than 60.53% of its industry peers.
XPEV's Return On Equity of -18.51% is in line compared to the rest of the industry. XPEV outperforms 57.89% of its industry peers.
Industry RankSector Rank
ROA -7%
ROE -18.51%
ROIC N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
XPEV Yearly ROA, ROE, ROICXPEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

XPEV has a better Gross Margin (16.14%) than 65.79% of its industry peers.
XPEV's Gross Margin has improved in the last couple of years.
XPEV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
XPEV Yearly Profit, Operating, Gross MarginsXPEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

3

2. Health

2.1 Basic Checks

XPEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
XPEV has more shares outstanding than it did 1 year ago.
XPEV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XPEV has a worse debt to assets ratio.
XPEV Yearly Shares OutstandingXPEV Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
XPEV Yearly Total Debt VS Total AssetsXPEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that XPEV is in the distress zone and has some risk of bankruptcy.
XPEV has a Altman-Z score of 1.34. This is in the better half of the industry: XPEV outperforms 71.05% of its industry peers.
XPEV has a Debt/Equity ratio of 0.65. This is a neutral value indicating XPEV is somewhat dependend on debt financing.
XPEV has a Debt to Equity ratio (0.65) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC13.28%
XPEV Yearly LT Debt VS Equity VS FCFXPEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B 40B

2.3 Liquidity

A Current Ratio of 1.25 indicates that XPEV should not have too much problems paying its short term obligations.
XPEV's Current ratio of 1.25 is in line compared to the rest of the industry. XPEV outperforms 52.63% of its industry peers.
XPEV has a Quick Ratio of 1.11. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XPEV (1.11) is better than 71.05% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.11
XPEV Yearly Current Assets VS Current LiabilitesXPEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.91% over the past year.
Looking at the last year, XPEV shows a very strong growth in Revenue. The Revenue has grown by 33.22%.
XPEV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 77.48% yearly.
EPS 1Y (TTM)48.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.28%
Revenue 1Y (TTM)33.22%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%23.41%

3.2 Future

Based on estimates for the next years, XPEV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.29% on average per year.
XPEV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.30% yearly.
EPS Next Y61.14%
EPS Next 2Y50.07%
EPS Next 3Y36.46%
EPS Next 5Y23.29%
Revenue Next Year94.64%
Revenue Next 2Y62.28%
Revenue Next 3Y44.07%
Revenue Next 5Y29.3%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XPEV Yearly Revenue VS EstimatesXPEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50B 100B 150B
XPEV Yearly EPS VS EstimatesXPEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XPEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XPEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XPEV Price Earnings VS Forward Price EarningsXPEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XPEV Per share dataXPEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as XPEV's earnings are expected to grow with 36.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.07%
EPS Next 3Y36.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XPEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XPENG INC - ADR

NYSE:XPEV (5/19/2025, 8:21:19 PM)

After market: 20.03 +0.05 (+0.25%)

19.98

-0.69 (-3.34%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)03-18 2025-03-18/bmo
Earnings (Next)05-21 2025-05-21/bmo
Inst Owners14.49%
Inst Owner Change1.93%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap18.99B
Analysts76.13
Price Target23.62 (18.22%)
Short Float %7.28%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.1%
Min EPS beat(2)-8.69%
Max EPS beat(2)-1.5%
EPS beat(4)1
Avg EPS beat(4)2.61%
Min EPS beat(4)-8.69%
Max EPS beat(4)26.7%
EPS beat(8)2
Avg EPS beat(8)-2.73%
EPS beat(12)3
Avg EPS beat(12)-7.3%
EPS beat(16)5
Avg EPS beat(16)-5.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.04%
Min Revenue beat(2)-1.46%
Max Revenue beat(2)1.37%
Revenue beat(4)1
Avg Revenue beat(4)-3.63%
Min Revenue beat(4)-11.83%
Max Revenue beat(4)1.37%
Revenue beat(8)1
Avg Revenue beat(8)-5.86%
Revenue beat(12)2
Avg Revenue beat(12)-5.55%
Revenue beat(16)6
Avg Revenue beat(16)-2.27%
PT rev (1m)3.49%
PT rev (3m)57.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.64%
EPS NY rev (1m)-2.46%
EPS NY rev (3m)15.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.09%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)11.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.35
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB 5.14
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS5.97
BVpS4.57
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7%
ROE -18.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.14%
FCFM N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 115.1%
Cap/Sales 5.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.11
Altman-Z 1.34
F-Score4
WACC13.28%
ROIC/WACCN/A
Cap/Depr(3y)230.67%
Cap/Depr(5y)363.23%
Cap/Sales(3y)10.3%
Cap/Sales(5y)14.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.28%
EPS Next Y61.14%
EPS Next 2Y50.07%
EPS Next 3Y36.46%
EPS Next 5Y23.29%
Revenue 1Y (TTM)33.22%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%23.41%
Revenue Next Year94.64%
Revenue Next 2Y62.28%
Revenue Next 3Y44.07%
Revenue Next 5Y29.3%
EBIT growth 1Y37.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.03%
EBIT Next 3Y38.51%
EBIT Next 5Y30.46%
FCF growth 1Y-227.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-310.46%
OCF growth 3YN/A
OCF growth 5YN/A